Mazen Darwazah Buys 315,000 Shares of Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Mazen Darwazah bought 315,000 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were purchased at an average cost of GBX 1,601 per share, with a total value of £5,043,150.

Mazen Darwazah also recently made the following trade(s):

• On Tuesday, September 16th, Mazen Darwazah purchased 14,000 shares of Hikma Pharmaceuticals stock. The stock was bought at an average price of GBX 1,603 per share, for a total transaction of £224,420.

Hikma Pharmaceuticals Stock Performance

Shares of HIK stock traded up GBX 46.64 during mid-day trading on Friday, reaching GBX 1,568.64. The stock had a trading volume of 152,980,813 shares, compared to its average volume of 1,997,314. The firm has a market cap of £3.47 billion, a PE ratio of 9.39, a P/E/G ratio of 2.38 and a beta of 0.41. Hikma Pharmaceuticals PLC has a one year low of GBX 1,522 and a one year high of GBX 2,360. The firm’s 50 day simple moving average is GBX 1,734.94 and its 200 day simple moving average is GBX 1,896.07. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. cut their price objective on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating for the company in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Berenberg Bank reduced their price target on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a report on Thursday, October 16th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,600 price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of GBX 2,615.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.